Cost-Effectiveness Analysis of a Bivalent RSVPreF Vaccine in Japanese Adults Aged 60 Years and Older
Abstract Introduction Respiratory syncytial virus (RSV) is a major cause of acute respiratory illness. A bivalent RSV prefusion F protein-based (RSVpreF) vaccine was approved in Japan to prevent RSV-related diseases in older adults in 2024. This study evaluated the cost-effectiveness of the RSVpreF...
Zapisane w:
| Główni autorzy: | , , , , , , |
|---|---|
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
Adis, Springer Healthcare
2025-07-01
|
| Seria: | Infectious Diseases and Therapy |
| Hasła przedmiotowe: | |
| Dostęp online: | https://doi.org/10.1007/s40121-025-01177-4 |
| Etykiety: |
Nie ma etykietki, Dołącz pierwszą etykiete!
|